Susquehanna International Group
IMDX

Susquehanna International Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Susquehanna International Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,645
Closed -$48K – 13851
2022
Q2 		$48K Sell
2,645
-765
-22% -$17.4K ﹤0.01% 11994
2022
Q1 		$102K Sell
3,410
-1,295
-28% -$41.4K ﹤0.01% 11899
2021
Q4 		$204K Buy
4,705
+5
+0.1% +$288 ﹤0.01% 11401
2021
Q3 		$335K Buy
4,700
+1,045
+29% +$96.1K ﹤0.01% 10337
2021
Q2 		$420K Buy
3,655
+820
+29% +$80.1K ﹤0.01% 10000
2021
Q1 		$294K Buy
2,835
+1,790
+171% +$170K ﹤0.01% 10645
2020
Q4 		$50K Buy
+1,045
New +$38.3K ﹤0.01% 10752

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group's IMDX Position: Q1 2026 in Review

Susquehanna International Group reduced its Insight Molecular Diagnostics (IMDX) stake by 23% in Q1 2026, selling an estimated $95K and leaving 56,093 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #11782.

Susquehanna International Group first reported a position in IMDX in Q1 2017 and has held it in 19 quarters since. The position peaked at $543K in Q4 2025. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Susquehanna International Group held 56,093 shares of Insight Molecular Diagnostics worth $184K as of Q1 2026.
  • Susquehanna International Group sold 16,358 Insight Molecular Diagnostics shares in Q1 2026, an estimated $95K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11782 holding.
  • Susquehanna International Group first reported a position in Insight Molecular Diagnostics in Q1 2017 and has held it in 19 quarters since.
  • Susquehanna International Group's Insight Molecular Diagnostics position peaked at $543K in Q4 2025.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.